euro adhoc: Restructuring & Recapitalisations / Ad Hoc (§15 WpHG): Epigenomics AG Increases Share Capital

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

11.02.2009

Berlin, Germany - Epigenomics AG (Frankfurt, Prime Standard: ECX;
ISIN: DE000A0BVT96) announces that the Executive Board and
Supervisory Board have resolved today to increase the share capital
of the company against contribution in cash and without subscription
rights. Epigenomics will place 2,671,088 new shares by way of a
direct private placement with institutional investors in Europe.
Epigenomics has received irrevocable commitments for the entire
placement by a 100% subsidiary of BB MEDTECH AG (Schaffhausen,
Switzerland) and funds managed by Abingworth LLP (London, UK)

The issue price has been set at EUR 1.94 per share. This constitutes
a 5% premium over and above the volume-weighted average XETRA trading
prices over the five trading days preceding the announcement of the
capital increase. The capital raise will yield gross proceeds of
approximately EUR 5.18 million. After registration of the capital
increase the signed capital of Epigenomics AG will increase from its
current EUR 26,723,636 to a total of EUR 29,394,724 thereafter.

Epigenomics intends to apply the proceeds from this transaction
towards the final stages of product development and commercialization
of its most advanced product, a blood-based molecular diagnostic test
for the early detection of colorectal cancer. Proceeds will also be
used for clinical R&D in its lung cancer and prostate cancer
programs.

Ende of Ad hoc-Announcement

Epigenomics' Legal Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

Disclaimer relating to US Securities Laws

The sale of the common stock will not be registered under the
Securities Act of 1933, as amended (the "Securities Act"), or
applicable state securities laws. The shares will be sold pursuant to
applicable exemptions from the registration requirements of the
Securities Act. Unless registered, the shares may not be offered or
sold in the United States except pursuant to an exemption from the
registration requirements of the Securities Act and applicable state
securities laws. This news release does not constitute an offer to
sell or the solicitation of an offer to buy the securities.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum

Sen. VP Corporate Development

Epigenomics AG

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade